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The aim of this study was to optimize the dose regimens of enrofloxacin to
reduce the development of fluoroquinolone resistance in Escherichia coli (E.coli)
using pharmacokinetic/pharmacodynamic (PK/PD) modeling approach. The single
dose (2.5mg/kg body weight) of enrofloxacin was administered intramuscularly (IM)
to the healthy pigs. Using cannulation, the pharmacokinetic properties, including
peak concentration (Cmax), time to reach Cmax (Tmax), and area under the curve
(AUC), were determined in plasma and ileum content. The Cmax, Tmax, and AUC in
the plasma were 1.09 ± 0.11µg/mL, 1.27 ± 0.35 h, and 12.70 ± 2.72µg·h/mL,
respectively. While in ileum content, the Cmax, Tmax, and AUC were 7.07 ± 0.26µg/mL,
5.54 ± 0.42 h, and 136.18 ± 12.50µg·h/mL, respectively. Based on the minimum
inhibitory concentration (MIC) data of 918 E. coli isolates, an E. coli O101/K99 strain
(enrofloxacin MIC= 0.25µg/mL) was selected for pharmacodynamic studies. The in vitro
minimum bactericidal concentration (MBC), mutant prevention concentration (MPC), and
ex vivo time-killing curves for enrofloxacin in ileum content were established against the
selected E. coli O101/K99 strain. Integrating the in vivo pharmacokinetic data and ex vivo
pharmacodynamic data, a sigmoid Emax (Hill) equation was established to provide values
for ileum content of AUC24h/MIC producing, bactericidal activity (52.65 h), and virtual
eradication of bacteria (78.06 h). A dosage regimen of 1.96mg/kg every 12 h for 3 days
should be sufficient in the treatment of E. coli.
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INTRODUCTION
The Escherichia coli was the most important pathogen for post-weaning diarrhea which can cause
the increase of mortality, morbidity and raising cost of pigs.
Enrofloxacin is a third generation fluoroquinolone developed byGuangdongHaikang veterinary
Ltd. in 1993 in China. As a broad-spectrum antimicrobial drug used in veterinary medicine,
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its principal applications have been for respiratory and
alimentary tract infections caused by gram-negative bacteria
(Giguère et al., 2013). With the widespread use of enrofloxacin in
husbandry and clinical setting, drug-resistant E. coli strains have
emerged. A recent report showed that about 40.5% of the clinical
E. coli isolated from pigs in Xinjiang was resistant to enrofloxacin
(Xia et al., 2012).
The development of resistance may largely due to the misuse
of antimicrobial agents (Burgess, 1999). The pharmacokinetics
and pharmacodynamics (PK/PD) modeling could provide
optimal dosage strategies and prevent resistance development.
PK/PD modeling is a key tool that can help identify the
clinically relevant relationship between time and effect. This
study investigated the PK and ex vivo PD activity of enrofloxacin
by using ileum content and plasma obtained from healthy pigs.
Cannulation of pig ileum was first used for studying
nutrient digestibility in 1973 (Holmes et al., 1974). The
simple-T cannulation method, which is widely used, has many
advantages over other cannulation procedures. In this method,
a hollow cannula is surgically inserted 8–10 cm anterior into
the ileocecal valve. Simple-T cannulation maintains a normal
physiological state, which is advantageous for research involving
the gastrointestinal tract (Wubben et al., 2001). It also enables
convenient ileum content sampling at different time points,
which allow direct prediction of drug concentration at the site
of action.
The aims of the present study were (i) to monitor the
pharmacokinetic properties of enrofloxacin in plasma and in
ileum contents after intramuscular (IM) dosing, (ii) to detect
the in vitro and ex vivo pharmacodynamic parameters of
enrofloxacin against pig source E. coli, and (iii) to determine a
rational dosage regimen for enrofloxacin against E. coli based
on PK/PD modeling. It is proposed that this dosage regimen
will provide maximal efficacy and minimal opportunity for the
emergence of resistant E. coli (Aliabadi et al., 2003).
MATERIALS AND METHODS
Animals
The study was carried out in six healthy male (castrated) pigs,
weighing 21–32 kg (mean = 27 kg and SD = 3.82) at an age
of 6–7 weeks. The pigs were placed in separate pens. Pigs had
free access to water and were fed antibiotic-free food twice
daily. Pigs were allowed a 7-day acclimation period prior to the
study. Animal housing was maintained at 25 ± 2◦C and 45–65%
relative humidity. All the animal experimental were approved
by Laboratory Animal Use and Care Committee in Hubei
Science and Technology Agency and performed according to the
committee guidelines. The anesthetics and other techniques were
used to reduce the pain and adverse effect of animal.
Drug Administration
The 50 mg/mL enrofloxacin solution purchased from Baytril
(Bayer AG, Leverkussen, Danmark). The approved label dose
(2.5mg/kg) was intramuscularly administrated to one side of the
neck of the pigs.
Insertion of Ileal Cannulation and Sampling
Procedures
The cannula was exteriorized on the right side of the pig
between the last two ribs (Wubben et al., 2001). The anesthesia
was administered intravenously at the dose of 15mg/kg and
maintained with ketamine. The cannula was composed of 10 cm
of medical grade rubber plastic tubing (acetal homopolymer
resin), with inner and outer diameters of 2 and 3 cm, respectively.
The large diameter end of the tubing was hand-tooled to provide
a flanged end with a concave inner surface to conform to the
shape of the ileum. All unthreaded areas on the cannula were
hand-finished for smooth the surfaces and edges where the
cannula would contact tissues. Pigs were allowed to recover
fully in the metabolism crates for 2 weeks and were provided
supplemental heat from an infrared heat lamp.
Blood samples (10mL) were collected in heparinized tubes
from the jugular catheter at 0 (pretreatment), 5, 15, 30, and
45min, and at 1, 2, 4, 6, 8, 10, 12, 24 h after enrofloxacin
administration. Keep the collection tubes on ice for 30min, and
then centrifuged at 2500 g, 4
◦
C for 10min. The collected plasma
samples were stored at−20◦C until assayed.
Ileum contents were collected into tubes from the ileal
cannulation at different time point (0, 15, 45min, 1, 2, 4, 6,
8, 12, 24, and 48 h) after enrofloxacin administration. Samples
were divided into two aliquots on ice and stored at −20◦C, for
subsequent PK/PD studies.
Establish High-Performance Liquid
Chromatography (HPLC) for Detecting
Drug Concentration
Plasma and ileum contents concentrations of enrofloxacin and
its metabolite ciprofloxacin were determined by using a Waters
2695 series reverse-phase HPLC as described previously (Janusch
et al., 2014).
One milliliter acetonitrile was added to 0.5mL plasma and the
solution was vortexed for 3min. Following centrifugation at 8000
g and 4◦C for 10min, the supernantant was evaporated to dryness
at 50◦C under nitrogen. The residue was reconstituted in 0.5mL
mobile phase and vortexed. A 40-µL aliquot of the reconstituted
sample was injected into the HPLC system. An Agilent SB-C18
column (250mm × 4.6mm i.d., 5µm) was used for separation.
The 0.1% formic acid and 13% acetonitrile were used as mobile
phase.
Two milliliters of 0.5M EDTA at pH 7.0 and 15mL of
dichloromethane were added to 1 g ileum content. The sample
was extracted in sealed 50mL tubes by shaking for 10min and
then centrifuged at 3500 g. The organic phase was collected and
the extraction repeated twice. Pool and dry the combined extracts
under nitrogen at 50◦C. Use 1mL mobile phase (0.1% formic
acid and 11.5% acetonitrile) to dissolve the samples. Maintain the
column temperature at 30 ± 5◦C. Set up the UV detector at a
wavelength of 278 nm. The injection volume and flow rate were
40µL and 1mL/min, respectively.
The standard curves of enrofloxacin and ciprofloxacin were
ranged from 0.04 to 1µg/mL (mg) with r2 > 0.999 in plasma
and ileum content. The limits of quantification (LOQ) were
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0.04µg/mL in plasma and 0.1µg/mg in ileum content. The
mean recovery of enrofloxacin and ciprofloxacin was >85% in
plasma samples and >70% in ileum content. The intra- and
interassay coefficients of variation were <9.6%. The specificity
of the method was good for the target substances. There was no
endogenous interference on chromatograms.
Pharmacokinetic Analysis
PK parameters for plasma and ileum content drug concentrations
were performed byWinNonlin software (version 5.2.1, Pharsight
Corporation, Mountain View, CA, USA). Drug concentrations
were plotted on semi-logarithmic graphs to choose appropriate
PK models. The most suitable compartmental model was
evaluated following the minimum Akaike’s information criterion
(Yamaoka et al., 1978). The one-compartment model was the
most appropriate model for all tested pigs. This model was used
to compute several PK parameters, including Cmax, Tmax, AUC
and so on. All data are presented as mean± SD.
Pharmacodynamics Analysis
Bacterial Strain
Nine hundred and eighteen E. coli strains were isolated from
pigs. These isolates were collected between 2012 and 2013 from
sources in Anhui, Henan, Jiangxi, Hubei, and Henan provinces.
According to the MIC90 values of sensitive strains, an E. coli
O101/K99 strain withMIC similar toMIC90, was used to study the
antimicrobial activity of enrofloxacin in vitro. E. coliATCC 25922
strain was used as reference strain for antibiotic susceptibility
determination. These strains were stored at−80◦C in our lab.
Determination of MIC, MBC, and MPC
In vitro
The minimal inhibitory concentration (MIC) was determined in
both broth and ileum content by microdilution according to the
CLSI guideline (CLSI, 2012). MIC was the lowest concentration
of enrofloxacin where visible bacterial growth was inhibited after
24 hours’ incubation.
To determine the minimal bactericidal concentration (MBC),
100µL suspension from the MIC determination wells were
successively 10 fold diluted in MH broth. The colony forming
unit (cfu) of each dilution was counted by spreading 10µL on
MH agar plates after 24 hours’ incubation at 37◦C. The MBC
was the lowest concentration of enrofloxacin which could reduce
99.9% bacterial density. The final result was expressed as mean of
five independent experiments.
The 1010 cfu/mL of E. coli was prepared to determine the
mutant prevention concentration (MPC) by the agar method
(Zhao and Drlica, 2001). Bacterial suspensions were spread on
the agars containing serial dilutions of enrofloxacin (1, 2, 4, 8, 16,
and 32MIC). After 96 hours’ incubation at 37◦C, theMPC can be
defined as the lowest concentration which could totally inhibited
bacterial growth under anaerobic conditions.
In vitro and Ex vivo Time-Killing Curves
For the in vitro time-killing curves, the tubes containing bacteria
(106 cfu/mL) and different concentrations of enrofloxacin (1/2
MIC–32 MIC) were co-incubated at 37◦C. The colony forming
units in the samples collected at different time point (0, 1, 2, 4, 8,
12, 18, and 24 h) was determined by bacteria agar counting.
For the ex vivo time-killing curves, the bacteria (106 cfu/mL)
were co-incubated with ileum content samples obtained from
pigs at different time point after treated by enrofloxacin. The
viable counts were determined at 0, 1, 2, 4, 8, 12, 18, and 24 h. The
time-killing curves obtained with ileum content were analyzed



















Where B is the number of bacterial cell expressed as cfu/mL; knet
the net growth rate; Bmax the maximum number of bacteria; Emax
the maximum killing rate; EC50, the concentration to reach half
of maximal killing rate; and γ, the steepness.
The ex vivo time-killing curve was fitted to this model with the
hypothesis of a decrease in enrofloxacin concentration according
to incubation time using the mlxplore software (version-1.1.0,
Lixoft, Orsay, France).
PK/PD Integration
The AUC24h/MIC and Cmax/MIC were used as the combined
PK/PD parameters. Using the following inhibitory sigmoid Emax
model to integrate the ex vivo AUC24h/MIC ratio and bacteria
count change (cfu/mL) in ileum content during 24 h incubation
(Aliabadi and Lees, 2001; Aliabadi, 2002; Aliabadi et al., 2003).
This model is described as follows:
E = Emax −
(Emax − E0) · C
N
CN + ECN50
In the above formula, the E means effect of antimicrobial agent
measured as log10 difference of bacterial number before and after
24 hours’ incubation in the ileum content sample; E0 and Emax
are the changes in log10 difference in bacterial count between 0
and 24 h in the control sample and in the enrofloxacin containing
samples, respectively. EC50 is the AUC24h/MIC value which
reached to 50% of the Emax; C is the tested AUC24h/MIC ratio;
and N is the Hill coefficient.
The ex vivo antibacterial effects of enrofloxacin administration
were quantified into three levels including: (1) bacteriostatic
action (no change in bacterial count, E = 0), (2) bactericidal
action (99.9% reduction in bacterial count, E = −1), and (3)
bacterial elimination (99.99 % reduction, E = −3) (Aliabadi
and Lees, 2001; Aliabadi et al., 2003; Aliabadi, 2002; Aliabadi





where AUC/MIC is the targeted end point for optimal efficacy;
MIC is minimum inhibitory concentration; CL is clearance per
day; fu is free fraction of drug in plasma (ignore if minimal
binding). In this study, the protein binding of enrofloxacin
can be discounted because the ileum content enrofloxacin
concentrations is higher than that in plasma. In other scientific
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literature (Nielsen andGyrd-Hansen, 1997) the bioavailability (F)
of enrofloxacin was 100%, so F may also be discounted.
To investigate the effect of different dosage regimens, the
PD model describing bacterial growth rate as a function of
enrofloxacin concentrationwas combinedwith the PKmodel and
simulations were performed with mlxplore software (version-
1.1.0, Lixoft, Orsay, France).
RESULTS
Pharmacokinetics of Enrofloxacin
Plasma and ileum content concentrations of enrofloxacin IM
administration are illustrated in Figure 1. The active metabolite
ciprofloxacin was not found in any sample.
After IM dosing, the plasma concentration of enrofloxacin was
best fitted with a mono-compartmental model (Table 1). Rapid
absorption of enrofloxacin was indicated by T½abs = 0.28 h.
Cmax was 1.09µg/mL, achieved at 1.27 h. The mean elimination
half-life (T½el) was 6.69 h. AUC24h was 12.7µg·h/mL. The mean
residence time (MRT) up to last was 8.48 h.
After IM dosing, the ileum content concentration of
enrofloxacin was also best fitted with a mono-compartmental
model (Table 1). T½el was 8.50 h, showing slow elimination
after IM administration. Cmax was 7.07µg/mL, achieved at
5.54 h. T½abs was 2.05 h. AUC24h was 136.18µg·h/mL. MRT was
14.38 h.
After IM administration, ileum content enrofloxacin
concentrations were significantly higher than those in plasma.
Pharmacodynamics
MIC, MBC, and MPC of Enrofloxacin against E. coli
Strains
The MIC50 and MIC90 of 918 strains isolated from pigs in
five provinces were 2 and 32µg/mL, respectively. Using CLSI
breakpoints, there were 178 susceptible E. coli isolates. The
MIC50 and MIC90 of theses trains were 0.125 and 0.25µg/mL,
respectively (Table 2). According to the MIC90 values of sensitive
strains, an E. coliO101/K99 strain with MIC similar to MIC90, was
used to study the antimicrobial activity of enrofloxacin in vitro.
MIC of enrofloxacin in MHB, plasma, and pig ileum content
to E. coli O101/K99 strain were 0.25, 0.25, and 0.5µg/mL,
respectively. Corresponding MBC values were 0.5, 1, and
2µg/mL, respectively. The MPC of enrofloxacin in MHB was
7.2µg/mL (Table 3).
TABLE 1 | Pharmacokinetics of enrofloxacin in plasma and ileum content
after IM administration (values are mean ± SD, n = 6).
Variable (units) Plasma Ileum content
AUC 12.70±2.72 136.18± 12.50
T½abs 0.28±0.10 2.05± 0.41
T½el 6.69±1.71 8.50± 1.66
Tmax 1.27±0.35 5.54± 0.42
Cmax 1.09±0.11 7.07± 0.26
V/F 2.17±1.16 0.22± 0.37
CL/F 0.20±1.08 0.072± 0.18
MRT 8.48±0.67 14.38± 0.03
AUC, Area under the concentration-time curve; T½abs, First order absorption rate
constant; T½el, First order elimination rate constant; CL/F, Systemic clearance; V/F,
Volume of distribution; MRT, Mean residence time.
TABLE 2 | Susceptibilities (MIC50 and MIC90) of 918 E. coli strains isolated
from pigs in Anhui, Henan, Jiangxi, Hubei, and Henan province, 2012–2013.
Antibiotic E. coli (n = 918)a E. coli (n = 178)b
MIC50 MIC90 Range MIC50 MIC90 Range
(µg/mL) (µg/mL) (µg/mL) (µg/mL) (µg/mL) (µg/mL)
Enrofloxacin 2 32 0.015–128 0.125 0.25 0.015–0.5
an, total number of isolates studied.
bn, susceptible strains based on the CLSI breakpoints.
TABLE 3 | MIC, MBC, and MPC (µg/mL) of enrofloxacin against E. coli
O101/K99.
Matrix MIC (µg/mL) MBC (µg/mL) MPC (µg/mL)
MHB 0.25 0.5 7.2
Plasma 0.25 1 –
Ileum content 0.5 2 –
FIGURE 1 | Enrofloxacin concentration-time profiles plotted for plasma, ileum content after IM administration. Values are mean ± SD (n = 6).
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FIGURE 2 | In vitro antibacterial activity of enrofloxacin against Escherichia coli in MHB.
FIGURE 3 | Ex vivo antibacterial activity of enrofloxacin in ileum content of swine against Escherichia coli after intramuscular administration (n = 6).
In vitro and Ex vivo Antimicrobial Activity
Time-killing curves obtained against E. coliO101/K99 for different
concentrations of enrofloxacin expressed as multiples of MIC
are showed in Figure 2. The curves are characteristics of
concentration-dependent antibiotic activity. The net growth
rate is lower for concentrations below 2 MIC. Meanwhile, the
bactericidal activity increased with increasing concentration of
enrofloxacin.
Ileum content samples from six pigs that had been
administered enrofloxacin intramuscular collected at different
time points were used to determine ex vivo killing rate. The
results show that at the highest concentration (at 6 h), the
number of bacteria decreased drastically (Figure 3). The growth
is observed for ileum content samples collected before 0.5 h and a
net killing rate is obtained with samples collected after 1 h. In the
data set with ileum content, a decrease in bacteria number was
shown in the ex vivo time-killing curves, however, a regrowth was
observed during the 24 hours’ incubation.
After fitting, the net killing rate was 0.69 h−1, knet = 0.35 h
−1,
the maximum number of bacteria Bmax was (10E8.16), Emax =
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2.3 h−1, EC50 = 0.35µg/mL, γ = 0.70 and enrofloxacin decrease
rate was 0.26 h−1.
PK/PD Integration
The PK/PD indices Cmax/MIC, AUC24h/MIC, Cmax/MPC, and
AUC24h/MPC of enrofloxacin against E. coli were integrated
using the PK parameters and MIC data in ileum content
(Table 4). The AUC24h obtained in this study was 136.18 ±
12.5µg·h/mL following a single dose IM administration of
enrofloxacin. The mean AUC24h/MIC ratio was 272.4 h. The
Cmax/MIC ratio was 14.1. The mean values for Cmax/MPC and
AUC24/MPC were 0.98 and 18.9, respectively.
PK/PD Modeling
In ileum content, the inhibitory sigmoid Emax model perfectly
described the relationship between antimicrobial efficacy of
enrofloxacin and the PK/PD parameter of AUC24h/MIC ratio.
Table 5 showed that the parameters obtained N, E0, Emax and
AUC24h/MIC values which respectively matched three level of
antibacterial activity. Ileum content values of AUC24h/MIC for
bacteriostatic activity, bactericidal action and virtual eradication
were 21.37, 52.65, and 78.06, respectively.
Estimation of Dose
Based on the bactericidal AUC24/MIC ratio (52.65 h) and MIC
of 0.5µg/mL in ileum content, an intramuscular dosage of
1.96mg/kg/day of enrofloxacin was calculated for bactericidal
activity against E. coli. Moreover, given an AUC24h/MIC ratio
for bacterial eradication (78.06 h), a dosage of 2.8mg/kg/day is
recommended to achieve virtual elimination of E. coli.
TABLE 4 | PK/PD integration parameters for enrofloxacin in ileum content
after intramuscular injection of enrofloxacin at a dose rate of 2.5mg/kg
(n = 6).





T>MIC h 33.54 ± 1.47
T>MBC h 16.89 ± 2.56
TABLE 5 | PK/PD Modeling of ex vivo data after administration of
enrofloxacin in pigs.
Parameter Units Mean ± SD
Emax h·µg/mL 2.23 ± 0.50
EC50 µg/mL 34.17 ± 3.26
E0 µg/mL −5.34± 0.13
N µg/mL 1.86 ± 0.39
Emax − E0 – 7.57 ± 0.98
Bacteriostatic (E = 0) – 21.37 ± 1.85
Bactericidal (E = −3) h 52.65 ± 3.78
Eradication (E = −4) h 78.06 ± 2.41
Assessment of Dose
Using a PK/PD model with the PD parameters derived from ex
vivo analysis, actions of different doses (0.78, 1.96, 2.8mg/kg)
were simulated (Figure 4). According to these figures, a dose of
0.78mg/kg is not sufficient to reduce the bacterial load while a
dose of 1.96mg/kg leads to a net reduction by a factor of 10
after 12 h.
Different dosage regimens for 3 days of treatment (0.78mg/kg
every 12 h, 1.96mg/kg every 12 h, and 2.8mg/kg every 24 h)
(Figure 5) were simulated. A dosage regimen of 1.96mg/kg every
12 h should be sufficient to reach bactericidal activity in ileum
content.
DISCUSSION
To obtain the best therapeutic effect and to prevent development
of resistance in bacteria, the design of dose regiment of
antimicrobial agents should be based on their PD and
PK properties. Previous PK studies only focused on the
plasma concentration of the active substance but ignored
the concentrations of antimicrobial agents in their target
sites. Innovatively, the pharmacokinetics parameters in
both plasma and ileum contents were analyzed in our
study.
For the plasma PK study only, the PK parameter (t1/2, Cmax,
and Tmax) obtained in this study were compared with the PK
values in previous studies (Pijpers et al., 1997; Richez et al.,
1997a,b; Zeng and Fung, 1997; Anadón et al., 1999; Wiuff et al.,
2002; Bimazubute et al., 2010) which also treated pigs by IM
injection of enrofloxacin at a single dose of 2.5mg/kg. The Cmax
and Tmax obtained in this study were 1.09µg/mL and 1.27 h,
respectively. The range of Cmax and Tmax value obtained in
the published literatures were 0.63–1.17µg/mL and 0.92–1.81 h,
respectively. Therefore, the Cmax and Tmax values seem to be
in the range of the values obtained previously. However, there
seemed some variability between the elimination half-life value
in our study (6.69 h) and in other published papers (4.1–13.1 h)
(Cox et al., 2004).
As far as we know, other authors have not studied
concentrations of enrofloxacin in ileum content. The ex vivo
ileum cannulation collection devices was firstly used in pigs for
our PK/PD study. In ileum content, the values of elimination
half-life, Cmax, and Tmax were 8.5 h, 7.07µg/mL, and 5.54 h,
respectively. The drug concentration in the intestinal contents
greatly exceeded that in chicken plasma (Scheer et al., 1997)
and in pig plasma (Lindecrona et al., 2000). The difference in
concentrations between plasma and intestinal contents could
be because of the high lipophilicity of enrofloxacin. The AUC
value showed that enrofloxacin had good penetration to various
tissues (Agersø et al., 1998). The ratio of ileum content to plasma
(based on AUC values) was 11.3. Enrofloxacin could penetrate
membranes and tissues, binding to solid parts of the ileum
content. Edlund et al. (1988) showed that up to 95% of the
measured norfloxacin concentration in human feces is bound
to anaerobic bacteria and solid parts of the feces. The relatively
higher binding in humans could be caused by a difference in the
composition of feces between humans and pigs.
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FIGURE 4 | Simulate the effect of different doses (0.78, 1.96, 2.8mg/kg). The effects of different doses were observed on bacteria and its elimination.
FIGURE 5 | Simulate different dosage regimen (0.78mg/kg every 24h, 1.96mg/kg every 12h and 2.8mg/kg every 24 h). The different doses were simulated
for different intervals of time to find the efficient dose and dose intervals.
Enrofloxacin is considered a concentration-dependent agent,
and its clinical efficacy is decided by dose and bacterial pathogen.
It has been proposed that the break points determining efficacy
of fluroquinolone are a Cmax/MIC ≥ 10 or an AUC24h/MIC
≥ 125 (Rodvold and Neuhauser, 2001). In the present study,
the sensitive E. coli obtained MIC50 and MIC90 levels in
the ranges of 0.25–0.5µg/mL, Cmax /MIC, and AUC24h/MIC
ratios for enrofloxacin in ileum contents were 14.1–28.2 and
272.4–544.7, respectively, indicating that the administration of
2.5mg/kg enrofloxacin may have a good antibacterial outcome
and could be set as an appropriate dose for treatment of E. coli
infection.
It has been proposed that the AUC24h/MPC ratio and T >
MPC should be selected as indicators for preventing the drug-
resistant mutants (Zhao and Drlica, 2001; Olofsson et al.,
2006). The AUC24h/MPC in our study (18.8 h) was more than
that obtained in the previous studies (9.7 h) conducted for
enrofloxacin against E. coli isolates of dog origin (Gebru et al.,
2011), and the Cmax/MPC ratio (0.99) calculated in our study was
close to that obtained in previous reports (1.4) for enrofloxacin
against E. coli (Gebru et al., 2011). Previous study demonstrated
that ciprofloxacin treatment at AUC/MPC ratios of 22 could
prevent the resistant mutants of E. coli with an inoculum sizes
of 1010 cfu/mL (Olofsson et al., 2006).
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A number of studies have found that the increasing level
of antimicrobial resistance in gut flora was mainly due to the
misuse of antimicrobial agents in unsuitable and/or irrespective
administration route (Nguyen et al., 2012; Zhang et al., 2013). It
is very important to optimize the dose regiment by considering
both the PK and PD parameters of antimicrobial agents. The
PK/PD combined model can provide dose optimization and
combine the relationship between in vitro and in vivo study.
According to our PK and PD parameters, the single dose required
to reach bacteriostatic, bactericidal and eradication activity were
0.78, 1.96, and 2.8mg/kg, respectively. After simulating different
dosage regimens, it was found that an every 12 h treatment of
1.96mg/kg enrofloxacin for 3 days could sufficiently clear E. coli
infection in pigs. Our model is depend on bacterial population
and PK parameters obtained from healthy animals. It may be
more wise to obtain more information about the population
pharmacokinetics of enrofloxacin to take into account all the
variability associated with animals and bacteria.
CONCLUSION
The purpose of our study was to estimate a dosage regimen
of enrofloxacin by IM administration that would be sufficient
for treatment of E. coli in pigs. The dosage regimen was
designed on a PK analysis and some PD studies in ileum
contents. PD parameters of enrofloxacin were derived
from the analysis of static time kill curves obtained ex
vivo. The dosage regimen was simulated using an Emax
model. As a concentration-dependent drug, this approach
for dose determination is better than the analysis of the
relationship between AUC/MIC value and the number of
viable bacteria after 24 h. A dosage regimen of 1.96mg/kg
every 12 h for 3-days should be sufficient in the treatment of
E. coli.
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